Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL3592150 | 1.00 | USP2 (0.53) | USP2KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3602483 | 0.94 | POLB (0.50) | KDM4EALDH1A1LMNAABCB1HPGD | |
| Oxalic Acid SCHEMBL3598353 | 0.88 | HRH3 (0.54) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB | |
| Oxalic Acid SCHEMBL3598359 | 0.88 | HRH3 (0.54) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL29009117 | 0.87 | LMNA (0.47) | USP2KDM4EALDH1A1SMN1; SMN2LMNA | |
| Oxalic Acid SCHEMBL3594969 | 0.85 | HRH3 (0.57) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB | |
| Oxalic Acid SCHEMBL3594974 | 0.85 | HRH3 (0.57) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB | |
| Oxalic Acid SCHEMBL3600469 | 0.82 | CYP1A2 (0.50) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB | |
| Oxalic Acid SCHEMBL3598170 | 0.82 | CYP1A2 (0.50) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB | |
| Oxalic Acid SCHEMBL3600180 | 0.82 | CYP1A2 (0.50) | KDM4EALDH1A1SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097392-B1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-03-13 | — | — | EP | claimed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | claimed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | claimed |
| EP-2097392-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | claimed |
| WO-2008055933-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | claimed |
| EP-2097392-B1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-03-13 | — | — | EP | disclosed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | disclosed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | disclosed |
| EP-2097392-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055933-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRK1, OPRD1 | USP2 3762/4885KDM4E 4787/4885ALDH1A1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.